FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease Read more
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel ADC Programs Read more
Nimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics Read more